Advertisement

IRVINE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI) announced today that a new multi-center study published in the International Peer-Reviewed Academic Journal, Acta Paediatrica, shows that a change in clinical practice with the use of Masimo SET pulse oximetry technology led to a significant reduction of severe Retinopathy of Prematurity (ROP)—a devastating eye disease resulting in partial or complete blindness—in premature newborns.  The study also confirmed that conventional pulse oximetry technology is not effective in reducing ROP, even when clinical practice is changed to reflect lowered oxygen saturation targets. (1)

ROP is the second leading cause of blindness in childhood in the United States—affecting over 20% of premature babies. (2) A major cause of ROP is the use of excess oxygen to treat respiratory problems in premature babies, which stimulates abnormal vessel growth within the eye.  Although the use of pulse oximetry is established as a standard-of-care technology for measuring oxygen saturation and appropriately titrating oxygen administration to prevent ROP, accuracy and reliability varies greatly by which pulse oximetry technology is used.  Masimo SET pulse oximetry technology is clinically-proven to measure-through motion and low perfusion, leading to accurate and reliable monitoring of oxygen saturation in premature newborns. Although previous clinical studies have shown a reduction in the incidence of ROP in premature newborns when Masimo SET pulse oximetry is used in combination with appropriate titration of oxygen administration, (3) (4) this is the first published study showing a head-to-head comparison of Masimo SET vs. another "next generation" pulse oximetry.

In the current study, researchers examined the role that SpO2 technology plays in the prevention of ROP in 571 high-risk premature

'/>"/>

SOURCE

Advertisement
Advertisement